sefulness of topical heparinoid in the treatment of asteatosis in hemodialyzed patients

Not Applicable

• Conditions: asteatosis in hemodialyzed patient

• Registration Number: JPRN-UMIN000029360
• Lead Sponsor: ippon medical school hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-10-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 76

Inclusion Criteria

Not provided

Exclusion Criteria

(1) Patients who received heparinoid- or urea -containing drugs, or petrolatum within three weeks before signing the consent form. (2) Patients with/ with the past of extensive complications of the skin (burn, psoriasis etc.) (3) Patients with allergy to heparinoid (4) Patients with hemorrhagic blood disease (hemophilia, thrombocytopenia, purpura etc.) (5) Patients who are expected a few bleeding causes a serious result. (6) Patients who are pregnant, or possibly pregnant women. (7)Patients who participated in other clinical study within 4 months before starting study. (8) Patients who are unsuitable to the study at the investigator's discretion.

Study & Design

• Study Type: Interventional
• Study Design: Not specified